Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 47,020
  • Shares Outstanding, K 46,554
  • Annual Sales, $ 0 K
  • Annual Income, $ -43,240 K
  • 60-Month Beta 1.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.51
Trade CRVS with:

Options Overview Details

View History
  • Implied Volatility 111.01% ( +0.57%)
  • Historical Volatility 119.31%
  • IV Percentile 37%
  • IV Rank 8.53%
  • IV High 463.98% on 06/09/22
  • IV Low 78.11% on 02/09/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 90
  • Volume Avg (30-Day) 22
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 2,668
  • Open Int (30-Day) 2,658

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.19
  • Number of Estimates 1
  • High Estimate -0.19
  • Low Estimate -0.19
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +32.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7501 +34.65%
on 06/24/22
1.2500 -19.20%
on 06/08/22
+0.0280 (+2.85%)
since 06/01/22
3-Month
0.7501 +34.65%
on 06/24/22
2.1100 -52.13%
on 04/05/22
-0.7600 (-42.94%)
since 04/01/22
52-Week
0.7501 +34.65%
on 06/24/22
9.5400 -89.41%
on 09/21/21
-1.6700 (-62.31%)
since 07/01/21

Most Recent Stories

More News
Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas Program covers scientific rationale, preclinical...

CRVS : 1.0100 (+2.01%)
Corvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York

Company to host a webcast at 9:00am ET / 6:00am PT...

CRVS : 1.0100 (+2.01%)
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Corvus to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. ...

CRVS : 1.0100 (+2.01%)
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT...

CRVS : 1.0100 (+2.01%)
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

BURLINGAME, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage...

CRVS : 1.0100 (+2.01%)
New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation

Data Presented in Poster Presentation at American Society of Hematology Annual Meeting...

CRVS : 1.0100 (+2.01%)
Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Results in patients with relapsed refractory NSCLC and head and neck cancer demonstrate tumor reduction in patients treated with mupadolimab mono and...

CRVS : 1.0100 (+2.01%)
Corvus: Q3 Earnings Snapshot

BURLINGAME, Calif. (AP) _ Corvus Pharmaceuticals Inc. (CRVS) on Monday reported a loss of $10.7 million in its third quarter.

CRVS : 1.0100 (+2.01%)
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results

BURLINGAME, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today...

CRVS : 1.0100 (+2.01%)
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

CPI-818 clinical trial in China will be conducted by Angel Pharmaceuticals...

CRVS : 1.0100 (+2.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible...

See More

Key Turning Points

3rd Resistance Point 1.1448
2nd Resistance Point 1.1019
1st Resistance Point 1.0559
Last Price 1.0100
1st Support Level 0.9670
2nd Support Level 0.9241
3rd Support Level 0.8781

See More

52-Week High 9.5400
Fibonacci 61.8% 6.1823
Fibonacci 50% 5.1451
Fibonacci 38.2% 4.1078
Last Price 1.0100
52-Week Low 0.7501

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar